HomeCompareBVXV vs PM

BVXV vs PM: Dividend Comparison 2026

BVXV yields 147.06% · PM yields 3.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BVXV wins by $22.55M in total portfolio value
10 years
BVXV
BVXV
● Live price
147.06%
Share price
$1.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.60M
Annual income
$9,667,205.19
Full BVXV calculator →
PM
Philip Morris International
● Live price
3.49%
Share price
$164.83
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,502.61
Full PM calculator →

Portfolio growth — BVXV vs PM

📍 BVXV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBVXVPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BVXV + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BVXV pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BVXV
Annual income on $10K today (after 15% tax)
$12,500.00/yr
After 10yr DRIP, annual income (after tax)
$8,217,124.41/yr
PM
Annual income on $10K today (after 15% tax)
$297.03/yr
After 10yr DRIP, annual income (after tax)
$2,127.22/yr
At 15% tax rate, BVXV beats the other by $8,214,997.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BVXV + PM for your $10,000?

BVXV: 50%PM: 50%
100% PM50/50100% BVXV
Portfolio after 10yr
$11.32M
Annual income
$4,834,853.90/yr
Blended yield
42.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

BVXV
No analyst data
Altman Z
-8.4
Piotroski
4/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.9% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BVXV buys
0
PM buys
5
PoliticianChamberTickerTypeAmountDate
Julia Letlow🏢 House$PM▼ Sell$1,001 - $15,0002026-02-05
Julie Johnson🏢 House$PM▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$PM▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$PM▼ Sell$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$PM▼ Sell$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$PM▲ Buy$1,001 - $15,0002025-09-29
Ro Khanna🏢 House$PM▲ Buy$15,001 - $50,0002025-09-05
Ro Khanna🏢 House$PM▲ Buy$15,001 - $50,0002025-08-26
Julie Johnson🏢 House$PM▼ Sell$1,001 - $15,0002025-08-14
Julie Johnson🏢 House$PM▼ Sell$1,001 - $15,0002025-07-22
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBVXVPM
Forward yield147.06%3.49%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$22.60M$49.6K
Annual income after 10y$9,667,205.19$2,502.61
Total dividends collected$20.88M$11.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: BVXV vs PM ($10,000, DRIP)

YearBVXV PortfolioBVXV Income/yrPM PortfolioPM Income/yrGap
1← crossover$25,406$14,705.88$11,650$409.56+$13.8KBVXV
2$62,102$34,917.38$13,592$497.49+$48.5KBVXV
3$146,216$79,767.65$15,882$605.21+$130.3KBVXV
4$331,975$175,523.78$18,589$737.41+$313.4KBVXV
5$727,658$372,444.73$21,794$899.94+$705.9KBVXV
6$1,541,551$762,956.42$25,597$1,100.16+$1.52MBVXV
7$3,160,048$1,510,588.88$30,118$1,347.30+$3.13MBVXV
8$6,275,251$2,893,998.93$35,505$1,652.97+$6.24MBVXV
9$12,085,478$5,370,960.29$41,940$2,031.88+$12.04MBVXV
10$22,598,667$9,667,205.19$49,643$2,502.61+$22.55MBVXV

BVXV vs PM: Complete Analysis 2026

BVXVStock

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Full BVXV Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this BVXV vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BVXV vs SCHDBVXV vs JEPIBVXV vs OBVXV vs KOBVXV vs MAINBVXV vs MOBVXV vs BTIBVXV vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.